Study: NCT02123615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: (%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: (%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: (%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: (%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: (%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: (%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: (%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: (%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 12
Description: Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 12
Description: Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 12
Description: Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 12
Description: Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 12
Description: Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 12
Description: Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 12
Description: Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 12
Description: Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 12
Description: Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 12
Description: Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 24
Description: Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 24
Description: Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 24
Description: Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 24
Description: Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 24
Description: Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 24
Description: Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 24
Description: Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 24
Description: Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 24
Description: Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 24
Description: Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 36
Description: Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 36
Description: Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 36
Description: Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 36
Description: Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 36
Description: Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 36
Description: Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 36
Description: Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 36
Description: Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 36
Description: Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subcutaneously at Week 36
Description: Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 12
Description: Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 12
Description: Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 12
Description: Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 12
Description: Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 12
Description: Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 12
Description: Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 12
Description: Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 12
Description: Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 12
Description: Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 12
Description: Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 24
Description: Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 24
Description: Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 24
Description: Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 24
Description: Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 24
Description: Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 24
Description: Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 24
Description: Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 24
Description: Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 24
Description: Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 24
Description: Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 36
Description: Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 36
Description: Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 36
Description: Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 36
Description: Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 36
Description: Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 36
Description: Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 36
Description: Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 36
Description: Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 36
Description: Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Gammagard subdermally at Week 36
Description: Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.